Table 4. Clinical status and NF-κB genotypic frequencies in 135 hepatocellular carcinoma (HCC) patients.
| Variable | NF-κB (All cases) | NF-κB (Male) | NF-κB (Female) | ||||||
| Del/Del (n = 29) | Del/Ins+ Ins/Ins (n = 106) | AOR (95% CI)a | Del/Del (n = 18 ) | Del/Ins+ Ins/Ins (n = 74) | AOR (95% CI)b | Del/Del (n = 11 ) | Del/Ins+ Ins/Ins (n = 32) | AOR (95% CI)b | |
| Clinical Stage | |||||||||
| Stage I/II | 15 (51.7%) | 69 (65.1%) | Reference | 9 (50.0%) | 42 (56.8%) | Reference | 6 (54.5%) | 27 (84.4%) | Reference |
| Stage III/IV | 14 (48.3%) | 37 (34.8%) | 0.536 (0.154–1.861) | 9 (50.0%) | 32 (43.2%) | 0.451 (0.073–2.786) | 5 (45.5%) | 5 (15.6%) | 0.218 (0.056–0.985)* |
| Tumor size | |||||||||
| ≤T2 | 16 (55.2%) | 71 (67.0%) | Reference | 10 (55.6%) | 43 (58.1%) | Reference | 6 (54.5%) | 28 (87.5%) | Reference |
| >T2 | 13 (44.8%) | 35 (33.0%) | 0.573 (0.166–1.975) | 8 (44.4%) | 31 (41.9%) | 0.688 (0.124–3.809) | 5 (45.5%) | 4 (12.5%) | 0.200 (0.041–0.981)* |
| Lymph node metastasis | |||||||||
| No | 27 (93.1%) | 101 (95.3%) | Reference | 16 (88.9%) | 70 (94.6%) | Reference | 11 (100%) | 31 (96.9%) | Reference |
| Yes | 2 (6.9%) | 5 (4.7%) | 0.351 (0.029–4.236) | 2 (11.1%) | 4 (5.4%) | 0.136 (0.005–3.383) | 0 (0%) | 1 (3.1%) | – |
| Distant metastasis | |||||||||
| No | 28 (96.6%) | 101 (95.3%) | Reference | 17 (94.4%) | 70 (94.6%) | Reference | 11 (100%) | 31 (96.9%) | Reference |
| Yes | 1 (3.4%) | 5 (4.7%) | 1.026 (0.060–17.488) | 1 (5.6%) | 4 (5.4%) | 0.356 (0.010–12.727) | 0 (0%) | 1 (3.1%) | – |
>T2: multiple tumor of >5 cm or tumor involving a major branch of the portal or hepatic veins.
a
The AORs with their 95% CIs were estimated by multiple logistic regression models after controlling for age, gender, smoking and drinking.
b
The AORs with their 95% CIs were estimated by multiple logistic regression models after controlling for age, gender, smoking and drinking.
*
P value <0.05 as statistically significant.